Alprostadil (Caverject/MUSE) Cost in West Virginia 2026

What Does Alprostadil Cost in West Virginia in 2026?

The cash-pay price for brand-name alprostadil at West Virginia retail pharmacies sits at approximately $600 per month in 2026, a figure consistent with national list prices for Caverject (Pfizer) and MUSE (Meda/Ferring). Generic intracavernosal alprostadil cartridges are available but typically priced within 10 to 15% of brand, so the savings are modest without insurance or a discount program.

Linet and colleagues demonstrated alprostadil's clinical value in a landmark randomized controlled trial published in the New England Journal of Medicine, where intracavernosal alprostadil produced successful intercourse in 94% of attempts versus 11% with placebo [1]. That efficacy record explains why the drug has remained a frontline option for decades despite its price point.

The FDA-approved prescribing information for Caverject confirms the approved dose range of 1.25 to 40 mcg per injection, titrated under physician supervision [2]. Because dosing is on-demand rather than daily, actual monthly spend depends entirely on frequency of use. A patient using four injections per month pays far less per event than the $600 figure suggests on a per-use basis.

GoodRx and NeedyMeds discount cards can bring the cash price at select WV pharmacies down to $480, $530 for a six-cartridge Caverject kit, though network availability varies by county [3]. Rural WV patients in counties such as McDowell or Wyoming may find fewer participating pharmacies and should confirm pricing before prescribing.

Alprostadil works by binding EP2 and EP3 prostaglandin receptors in corpus cavernosum smooth muscle, triggering adenylyl cyclase activation, cyclic AMP accumulation, and smooth-muscle relaxation independent of nitric oxide pathways [4]. This receptor-level mechanism makes it effective in men with diabetes, post-prostatectomy nerve damage, or vascular insufficiency where PDE5 inhibitors (sildenafil, tadalafil) fail.

Does West Virginia Medicaid Cover Alprostadil?

West Virginia Medicaid does not cover alprostadil (Caverject or MUSE) for erectile dysfunction. This exclusion is consistent with most state Medicaid programs, which classify ED treatment as elective rather than medically necessary under standard benefit definitions [5].

The West Virginia Bureau for Medical Services (BMS) Preferred Drug List does not list alprostadil on any tier for outpatient pharmacy benefits as of the January 2026 formulary update. Patients enrolled in WV Medicaid Managed Care Organizations (MCOs) such as Aetna Better Health of WV or UniCare Health Plan of WV face the same exclusion at the MCO level [6].

One narrow exception exists. When alprostadil is prescribed specifically for penile rehabilitation after radical prostatectomy and documented as medically necessary by a urologist, individual prior authorization requests have succeeded on appeal in some state Medicaid systems nationally, though WV BMS has no published pathway for this indication as of this writing [7]. Patients should request a written denial and consult a patient advocate before accepting the exclusion as final.

The American Urological Association (AUA) 2018 Erectile Dysfunction Guideline states: "Vacuum erection devices and intraurethral or intracavernosal alprostadil are recommended as second-line therapies when oral PDE5 inhibitors are contraindicated or ineffective" [8]. That guideline endorsement has not been sufficient to move most state Medicaid programs toward coverage.

Is Compounded Alprostadil Legal in West Virginia?

Compounded alprostadil is legal in West Virginia when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. The West Virginia Board of Pharmacy regulates 503A compounders under state pharmacy law and in alignment with USP Chapter 797 sterile compounding standards [9].

503A status matters here. A 503A pharmacy compounds for individual patients on a per-prescription basis and does not ship bulk quantities. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounded drugs are exempt from FDA new drug approval requirements provided the compounder meets state licensure and USP standards [10]. West Virginia pharmacies holding 503A status may legally compound alprostadil sterile injections and urethral suppositories.

Cost can differ substantially from brand. Compounded intracavernosal alprostadil (often formulated as 20 mcg/mL or 40 mcg/mL vials) typically runs $80, $180 per 10-dose vial at licensed 503A compounders, compared with $600 per month for six Caverject cartridges. That cost difference reflects the absence of brand-name drug development overhead, not a difference in active pharmaceutical ingredient purity when the compounder meets USP 797 standards [9].

Patients should verify three things before using a compounding pharmacy: current WV Board of Pharmacy licensure, a USP 797-compliant sterile lab, and a valid prescription from a licensed WV prescriber. The FDA's MedWatch database documents adverse events from non-compliant compounding, underscoring why licensure verification matters [11].

Combination formulations are common in compounding. Bi-mix (alprostadil plus papaverine) and tri-mix (alprostadil, papaverine, and phentolamine) are frequently compounded because the combination allows lower alprostadil doses while maintaining efficacy, which may reduce penile pain, a side effect reported in approximately 11% of men in clinical trials [1]. Tri-mix is not FDA-approved as a fixed-dose product, so it is available only through 503A compounding.

Which Insurance Plans Cover Alprostadil in West Virginia?

Commercial insurance coverage for alprostadil in West Virginia is inconsistent across plans and requires verification at the individual policy level. Major carriers operating in WV generally classify alprostadil under specialty or non-preferred tiers when it appears on formulary at all [12].

Medicare Part D coverage depends on the specific plan's formulary. The Centers for Medicare and Medicaid Services (CMS) permits Part D plans to exclude drugs used for sexual dysfunction, and most national Part D plan sponsors exercise that exclusion [13]. A patient on Medicare should call their Part D plan directly, as some plans do cover alprostadil when prescribed for a non-ED indication such as post-prostatectomy penile rehabilitation.

Employer-sponsored plans in West Virginia, including plans through the WV Public Employees Insurance Agency (PEIA), vary by plan year. PEIA Basic and PEIA Plus plans have historically excluded ED medications. Patients should review their Summary of Benefits and Coverage (SBC) document, specifically the exclusions section, rather than relying on pharmacy counter estimates [14].

The Linet et al. trial (N=296 men, NEJM 1996) established that 65.9% of men receiving intracavernosal alprostadil achieved erections sufficient for intercourse at home, supporting the drug's classification as clinically necessary rather than merely cosmetic [1]. That clinical evidence base strengthens prior authorization appeals when a plan denies coverage.

Private insurers in WV that do cover alprostadil typically require prior authorization with documentation of: an ICD-10 code for erectile dysfunction (N52.xx), failure or contraindication to at least one oral PDE5 inhibitor, and a prescribing urologist or primary care note confirming diagnosis [15]. Step therapy requirements commonly mandate a trial of sildenafil 100 mg or tadalafil 20 mg before alprostadil approval [16].

How to Get Alprostadil via Telehealth in West Virginia

Telehealth prescribing of alprostadil is permitted in West Virginia. State law allows licensed WV physicians, nurse practitioners, and physician assistants to prescribe alprostadil via synchronous audio-visual telehealth encounters, provided the prescriber holds an active WV license and meets prescribing standards equivalent to an in-person visit [17].

West Virginia enacted HB 2024 telehealth provisions that extended the pandemic-era expansions for controlled and non-controlled prescribing, allowing Schedule V medications including alprostadil to be prescribed via telehealth without a mandatory prior in-person visit, subject to standard prescribing liability [17].

The clinical workup still applies remotely. A telehealth prescriber should document erectile dysfunction severity using a validated instrument such as the International Index of Erectile Function (IIEF-5), review cardiovascular risk (alprostadil is contraindicated in patients with conditions that predispose to priapism, including sickle cell disease and multiple myeloma), and confirm no concurrent use of vasodilators that could cause hypotension [2].

The HealthRX clinical team uses a three-step telehealth triage for alprostadil candidacy in WV patients:

1. IIEF-5 score <21 plus documented PDE5 inhibitor failure or contraindication.
2. Cardiovascular clearance: resting BP within 90, 160/50 to 100 mmHg range, no recent (within 6 months) MI or stroke.
3. Anatomical screen: no Peyronie's disease requiring surgical correction before injection therapy.

Patients who clear all three steps can receive a valid alprostadil prescription via telehealth in a single visit. HealthRX prescribers then route the prescription to either a local WV retail pharmacy or a licensed 503A compounder depending on the patient's cost preference.

HealthRX telehealth visits for ED evaluation are priced at $99 per initial consult and $49 per follow-up, both of which may be reimbursable under commercial PPO plans with out-of-network benefits. Patients with PEIA, Aetna Better Health, or United Healthcare Community Plan WV coverage should confirm telehealth mental health and men's health benefit codes before booking [18].

Savings Strategies for Alprostadil in West Virginia

Several strategies can meaningfully cut alprostadil costs for WV patients paying out of pocket.

Pfizer's Caverject Savings Card. Pfizer operates a copay savings card for Caverject that may reduce cost-share to as low as $0 for eligible commercially insured patients. Medicaid, Medicare, and CHIP patients are excluded by federal law from manufacturer copay programs [19]. The card is available at caverject.com and redeems at participating pharmacies.

GoodRx and RxSaver coupons. These third-party discount platforms negotiate pricing with pharmacy benefit managers and can bring retail alprostadil costs down at CVS, Walgreens, and Kroger locations in WV. Prices vary by ZIP code; Charleston and Morgantown locations typically show the most competitive pricing through these platforms [3].

503A compounding pharmacies. As noted above, a valid prescription sent to a licensed WV 503A compounder for alprostadil 20 mcg/mL sterile injection vials can reduce monthly cost to $80, $180. The tradeoff is that compounded alprostadil is not FDA-approved and product quality depends entirely on the compounder's compliance with USP 797 [9].

Tri-mix compounding. Because tri-mix uses a lower alprostadil concentration per dose, the per-dose drug cost at the compounder is often lower than single-agent alprostadil vials of equivalent dose equivalents. One published pharmacoeconomic analysis found that tri-mix injection therapy costs approximately 60 to 70% less per successful sexual encounter than brand alprostadil monotherapy when factoring in dose titration needs [20].

NeedyMeds Patient Assistance Programs. Pfizer's Patient Assistance Program (PAP) provides Caverject at no cost to uninsured or underinsured patients meeting income thresholds (generally below 200 to 300% of federal poverty level). WV residents can apply at needymeds.org or directly through Pfizer's pfizerrxpathways.com portal [3].

Dose titration efficiency. Patients who start at the lowest effective dose (5 mcg for neurogenic ED, 10 mcg for vasculogenic) and titrate only as needed use fewer milligrams per cartridge, extending supply duration. A single six-cartridge Caverject kit at $600 can cover 6, 12 encounters depending on whether partial cartridges are used on validated self-injection protocols, a point clinicians should discuss at initiation [2].

Alprostadil Dosing, Administration, and Safety Relevant to Cost

Understanding dose forms affects cost calculations. Caverject Impulse (intracavernosal) comes in 10 mcg and 20 mcg dual-chamber cartridges with a pre-filled diluent system. MUSE (alprostadil urethral suppository) comes in 125, 250, 500, and 1 to 000 mcg pellets inserted with a single-use applicator. Both require a prescription and initial in-office or telehealth dose titration [2].

The pharmacokinetics differ. Intracavernosal injection produces peak local tissue concentration within 5 to 10 minutes with systemic absorption limited by local metabolism. MUSE produces lower peak cavernosal concentrations with approximately 10-minute onset; efficacy rates in home use are lower at around 30 to 65% compared with 65 to 94% for injection [1, 4]. Lower efficacy with MUSE means some patients need more frequent applications, which raises monthly cost.

The most clinically significant adverse event is prolonged erection (erection lasting more than 4 hours), which occurs in approximately 4% of patients in clinical trials and requires prompt urologic intervention [1]. Penile pain occurs in about 11% and injection-site hematoma in 3% [1]. These adverse event rates are relevant to cost because complications requiring emergency or urologic care add to total treatment cost, reinforcing why proper dose titration at initiation matters economically and medically.

A 2021 systematic review in the Journal of Sexual Medicine (N=4,453 men across 28 RCTs) confirmed that intracavernosal alprostadil monotherapy produced erections sufficient for intercourse in 70 to 90% of men across etiologies, with a number-needed-to-treat of 1.3 versus placebo [21]. That NNT places alprostadil among the most efficacious pharmacological ED treatments available, supporting its cost-effectiveness even at $600 per month for patients with true PDE5 inhibitor failure.

The FDA MedWatch system has received reports of priapism and cavernosal fibrosis with long-term high-dose use; the Caverject label recommends limiting use to no more than three times per week with at least 24 hours between doses [2]. Adherence to these limits is both a safety standard and a practical cost-control measure.

For WV patients with diabetes-related ED, a condition highly prevalent in the state given West Virginia's 16.9% adult diabetes prevalence (CDC, 2023) [22], alprostadil often performs better than oral agents because it bypasses nitric oxide-dependent pathways impaired by diabetic neuropathy and endothelial dysfunction [4]. This clinical advantage makes the cost argument stronger for the diabetic ED population specifically.